Wellington Management Group LLP Purchases 909,998 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Wellington Management Group LLP raised its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 3,025.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 940,077 shares of the company's stock after acquiring an additional 909,998 shares during the period. Wellington Management Group LLP owned approximately 1.53% of Protagonist Therapeutics worth $36,287,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of PTGX. Arrowstreet Capital Limited Partnership increased its holdings in Protagonist Therapeutics by 36.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock worth $8,340,000 after acquiring an additional 58,002 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Protagonist Therapeutics by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock valued at $22,327,000 after buying an additional 12,906 shares in the last quarter. Barclays PLC grew its holdings in Protagonist Therapeutics by 223.6% during the 3rd quarter. Barclays PLC now owns 126,995 shares of the company's stock valued at $5,714,000 after buying an additional 87,755 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock valued at $1,112,000 after buying an additional 300 shares in the last quarter. Finally, Victory Capital Management Inc. grew its holdings in Protagonist Therapeutics by 84.1% during the 4th quarter. Victory Capital Management Inc. now owns 240,817 shares of the company's stock valued at $9,296,000 after buying an additional 110,020 shares in the last quarter. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Stock Up 1.0%

PTGX traded up $0.51 during trading on Wednesday, reaching $51.57. The company had a trading volume of 257,790 shares, compared to its average volume of 888,196. The stock has a market cap of $3.20 billion, a P/E ratio of 19.39 and a beta of 2.65. The business has a 50 day simple moving average of $45.29 and a 200-day simple moving average of $42.74. Protagonist Therapeutics, Inc. has a 52 week low of $28.96 and a 52 week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The company had revenue of $28.32 million during the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. As a group, equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PTGX. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday. JMP Securities reaffirmed a "market outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. JPMorgan Chase & Co. raised their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a report on Monday, March 3rd. Finally, Wall Street Zen lowered shares of Protagonist Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Protagonist Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $65.44.

Insider Buying and Selling

In other news, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares in the company, valued at approximately $4,676,140.08. This trade represents a 26.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Asif Ali sold 1,756 shares of Protagonist Therapeutics stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $46.00, for a total value of $80,776.00. Following the sale, the chief financial officer now owns 61,065 shares of the company's stock, valued at approximately $2,808,990. This trade represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,173 shares of company stock worth $3,461,180 over the last three months. 4.90% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.